Genzyme Corporation

Shepherd Therapeutics, Inc.

William M Siders

Bruce Lindsay Roberts

William Harold Brondyk

Johanne Kaplan

Srinivas Shankara

Bruce L Roberts

Jamie Dempsey Barber

Katherine Arline

Johanne M Kaplan

The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.

Anti-human CD52 immunoglobulins

The disclosure relates to a method of treating cancer by administering to the subject a therapeutically effective amount of a composition comprising pyrvinium pamoate, optionally in combination with at least one additional therapeutic agent or modality.

Pyrvinium pamoate therapies and methods of use

The invention provides methods of treating lupus in a patient with an anti-CD52 antibody. Also includes are methods of increasing infiltration of regulatory T cells to affected sides of the patient's body, methods of reducing urine protein and/or albumin levels and methods of depleting lymphocytes to alleviate lupus symptoms.

Methods and compositions for treating lupus

Growing community of inventors

Franklin, MA, United States of America

William M Siders